← All trials
NCT04405388
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 25, 2020
- Primary completion
- Nov 15, 2021
- Completion date
- Nov 15, 2021
- First posted
- May 28, 2020
- Last posted
- May 28, 2020
- Enrollment
- 46
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Medical University of GrazLead sponsor
- University of TuebingenCollaborator
- Institut National de la Santé Et de la Recherche Médicale, FranceCollaborator
- University of ZurichCollaborator
- Medical University of GrazOverall official - principal investigator
- Medical University of GrazStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.